KẾT QUẢ ĐIỀU TRỊ BƯỚC MỘT BẰNG PEMBROLIZUMAB KẾT HỢP PACLITAXEL - CARBOPLATIN TRÊN BỆNH NHÂN UNG THƯ PHỔI KHÔNG TẾ BÀO NHỎ GIAI ĐOẠN IV

Abstract

Objectives: To analyze the efficacy of first-line pembrolizumab in combination with paclitaxel - carboplatin regimen for patients with stage IV non-small cell lung cancer (NSCLC) treated at Vietnam National Cancer Hospital. Methods: A retrospective and prospective, descriptive study was conducted on 48 patients with stage IV NSCLC who received first-line pembrolizumab plus paclitaxel - carboplatin between January 2020 and December 2024. Results: The mean age of the study population was 63.5 years; the majority were male (77.1%), and 64.6% had a history of smoking. The disease control rate was 95.8%, while the objective response rate (ORR) reached 72.9%. Median progression-free survival (PFS) was 8.5 months, and median overall survival (OS) was 20.2 months, with a 3-year OS rate of 42.6%. Most adverse events were mild to moderate (grade 1 - 2); grade 3 toxicities were infrequent (2 - 4%), and no grade 4 toxicities were observed. Immune-related adverse events were rare and mild. Conclusion: The combination of pembrolizumab with paclitaxel - carboplatin demonstrated encouraging clinical efficacy and an acceptable safety profile as first-line therapy for patients with stage IV NSCLC.